Ascletis Announces Positive Phase I Clinical Results of Oral RdRp Inhibitor ASC10 for COVID-19
- Written by PR Newswire
--The exposure of active drug ASC10-A after twice daily dosing 800 mg double prodrug ASC10 in Chinese subjects was 94% of that after twice daily dosing 800 mg single prodrug molnupiravir in Japanese subjects
--Based on Ascletis' Phase I results of ASC10 and molnupiravir's clinical efficacy data in American, Japanese and Chinese patients, 800 mg...














